Pacific Edge Appoints Tony Barclay to its Board

Company Announcement
17 MARCH 2022

PACIFIC EDGE APPOINTS TONY BARCLAY TO ITS BOARD
Cancer diagnostics company Pacific Edge (NZX: PEB, ASX: PEB) today announces the appointment of Tony
Barclay as an Independent Non-Executive Director.
Mr Barclay, who takes up the role on 21 March 2022, is a highly experienced healthcare industry leader.
He brings to Pacific Edge deep experience of taking innovative New Zealand technology to international
markets, including the US.
He was formerly Chief Financial Officer and Company Secretary of Fisher & Paykel Healthcare (FPH) from
when the healthcare business was separated from Fisher & Paykel Appliances in 2001. From then he led
the finance team and was a member of the senior leadership team until 2018, a period which saw FPH
grow to be one of the largest and most successful companies on the NZX.
He is currently Independent Chair of Izon Science, a world leading Christchurch-based manufacturer of
nano-biological separation and characterisation tools and Chair of Australian-based Baymatob, a pioneer
in women’s health and AI-guided monitoring for pregnancy and labour. He is also an Independent Director
of Veriphi, an Auckland-based technology company developing intravenous drug identity and
concentration verification devices.
Pacific Edge Chair Chris Gallaher said: “We are delighted Tony has agreed to join the Pacific Edge Board.
He brings to the company world-class corporate finance expertise and a deep understanding of the
challenges fast growing healthcare technology companies face taking their products to the world.
“We expect these perspectives will be of enormous value as Pacific Edge works to incorporate Cxbladder
technologies into global standards of care for urolthelial cancer and drives towards their adoption by
clinicians and healthcare providers around the world.”
Mr Barclay said: “I am looking forward to joining the Pacific Edge board. Cxbladder offers clinicians and
healthcare providers a compelling proposition. The suite of tests offers clinicians accurate, reliable, cost-
effective, non-invasive urothelial cancer diagnostic tools that are backed by a growing body of high-quality
peer-reviewed clinical evidence. I am looking forward to working with the team to realise the enormous
opportunities the company enjoys around the world.”
Mr Barclay has been a Chartered Accountant in New Zealand since 1990 and is a member of the Institute
of Directors and the Institute of Financial Professionals New Zealand (INFINZ). He received his Bachelor of
Commerce degree in accounting and finance from the University of Otago, New Zealand.
Images of Mr Barclay can be downloaded from the following link:
https://www.dropbox.com/s/tg58i3ubmg3ouup/Tony%20Barclay.jpg?dl=0
Released for and on behalf of Pacific Edge by Grant Gibson, Chief Financial Officer.

Company Announcement
17 MARCH 2022
For more information
Investors: Media:
Chris Gallaher Richard Inder
Chair The Project
Pacific Edge P: +64 21 645 643
P: +61 417 556 691
OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.